A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer: EORTC-GU Group Protocol 30867

• Published in: European journal of cancer & clinical oncology Vol. 25; no. 2; pp. 389 - 390
• Main Authors: FOSSA, S. D, SPLINTER, T, ROOZENDAAL, K. J, VEENHOF, K. H. N, PAVONE-MACALUSO, M, CALCIATI, A, DE PAUW, M, SYLVESTER, R
• Format: Journal Article
• Language: English
• Published: Oxford Pergamon Press 01.02.1989; New York, NY
• Subjects: Adult; Aged; Antineoplastic agents; Biological and medical sciences; Carcinoma, Transitional Cell - drug therapy; Chemotherapy; Drug Evaluation; Epirubicin - adverse effects; Epirubicin - therapeutic use; Female; Humans; Leukopenia - chemically induced; Male; Medical sciences; Middle Aged; Nausea - chemically induced; Pharmacology. Drug treatments; Thrombocytopenia - chemically induced; Urinary Bladder Neoplasms - drug therapy; Antineoplastic agent; Human; Chemotherapy; Urinary system disease; Treatment; Urinary bladder; Toxicity; Phase II trial; Advanced stage; Tumor; Anthracyclins; Transitional cell carcinoma
• ISSN: 0277-5379
• DOI: 10.1016/0277-5379(89)90035-7

There is, a need to identify drugs with cytotoxic activity in bladder cancer which are tolerable even in patients with impaired renal function. Adriamycin (ADM) is recognized as such an active drug, and 4-epi-adriamycin (epi-ADM) has been developed as its less toxic analogue. Therefore the EORTC GU Group performed a phase II study of epi-ADM in advanced urothelial cancer (EORTC Protocol 30867). Forty patients were entered in this study by 11 institutions.